Sugi Predict

Sugi Predict / Compounds / SCHEMBL1128710

SCHEMBL1128710

SCHEMBL1128710

CC1(C)OB(c2ccc(Oc3ccccc3)c([N+](=O)[O-])c2)OC1(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 8/20 0.47
▸ KMT2A Q03164 8/20 0.47
▸ MAPT P10636 8/20 0.47
▸ ALDH1A1 P00352 6/20 0.47
▸ HSPB1 P04792 2/20 0.47
▸ HPSE Q9Y251 1/20 0.46
▸ LMNA P02545 6/20 0.45
▸ THRB P10828 2/20 0.43
▸ TTR P02766 1/20 0.43
▸ ALB P02768 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ POLB P06746 3/20 0.43
▸ HTT P42858 3/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ LPL P06858 2/20 0.42
▸ LIPG Q9Y5X9 2/20 0.42
▸ KDM4E B2RXH2 4/20 0.40
▸ HPGD P15428 3/20 0.40
▸ GLA P06280 3/20 0.40
▸ GAA P10253 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18582781 0.90 HTR6 (0.48) MEN1KMT2AMAPTALDH1A1HSPB1
SCHEMBL4365538 0.85 L3MBTL1 (0.48) MEN1KMT2AMAPTALDH1A1HSPB1
SCHEMBL4771663 0.83 ALDH1A1 (0.45) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL29845809 0.83 ALDH1A1 (0.45) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL27037558 0.82 POLB (0.48) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL1129289 0.79 LIPG (0.49) LPLLIPGHIF1A
SCHEMBL22647885 0.78 LIPG (0.53) MAPTALDH1A1THRBTDP1POLB
SCHEMBL7813399 0.78 MEN1 (0.72) MEN1KMT2AMAPTALDH1A1HSPB1
SCHEMBL1129141 0.78 TTR (0.48) ALDH1A1TTRHTTLPLLIPG
SCHEMBL4366318 0.78 LPL (0.47) HSPB1LPLLIPGSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 — — US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 — — EP disclosed
EP-2283020-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI Pharmaceuticals, Inc. (US) 2011-02-16 — — EP disclosed
WO-2009143051-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-26 — — WO disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 — — US disclosed
US-6713474-B2 SERINE-THREONINE AND TYROSINE KINASE INHIBITORS ABBOTT GMBH & CO. KG (DE) 2004-03-30 — — US disclosed
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-08-14 — — US disclosed
WO-2001072751-A1 PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2001-10-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents FLT1, FLT4, TFPI MEN1 2108/4885KMT2A 2637/4885MAPT 2295/4885
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 MEN1 374/4885KMT2A 1103/4885MAPT 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.